DARREN KEMPTON: Open Payments
NPI 1902233208 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,861 in 19 payments from 10 companies in 2025. Trend: 2023 $741 · 2024 $910 · 2025 $1,861
Food & beverage: $1,861
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $556 |
| UCB, Inc. | 4 | $332 |
| Incyte Corporation | 2 | $264 |
| ABBVIE INC. | 2 | $163 |
| Amgen Inc. | 1 | $122 |
| KYOWA KIRIN, INC. | 1 | $120 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $97 |
| Boston Scientific Corporation | 1 | $77 |
| Access Pro Medical, LLC | 1 | $72 |
| Janssen Scientific Affairs, LLC | 1 | $56 |
Products named: DUPIXENT, OPZELURA, Bimzelx, SKYRIZI, POTELIGEO, WAYRILZ, SPEVIGO, ACCOLADE SR.
Industry payments across TX — which companies pay providers there.
